Methodology of clinical trials in dementia. Part I: Analysis of previous trials

  • J. M. S. Pearce
  • M. G. Wallace
  • R. Capildeo


With increasing life expectancy, dementia is rapidly becoming one of the greatest problems facing modern society: catastrophic for the patient, and a severe burden for the family, community and state. In a recent report from the UK, a College Committee on Geriatrics of the Royal College of Physicians has calculated that between 1976 and 1988 the over-65 population is projected to increase by 7% nationally. This conceals, however, a real increase of 25% in the over-75s who will then form 6.4% of the total population. Thus, in the UK, a health district of 250 000 people will have to provide services for 3000 elderly people suffering from dementia.


Ergot Alkaloid Senile Dementia Judgement Criterion Vertebrobasilar Insufficiency Cerebrovascular Insufficiency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Cox, J. R. (1975). Double-blind evaluation of naftidrofuryl in treating elderly confused hospitalised patients. Gerontol. Clin., 17, 160–67.CrossRefGoogle Scholar
  2. Fogelholm, R., Waltimo, O., Putkonin, A. R. and Lansonen, R. (1974). Ben-cyclan — a new vasodilator drug — in the treatment of patients with ischaemic cerebral infarction. Ann. Clin. Res., 6, 93–6.Google Scholar
  3. Gerin, J. (1974). Double-blind trial of naftidrofuryl in the treatment of cerebral arteriosclerosis. Brit. J. Clin. Pract., 28, 177–8.Google Scholar
  4. Hollister, L. (1983). Clinical trials of co-dergocrine in senile dementia. Brit. J. Clin. Prac, Suppl. 30, 41–5.Google Scholar
  5. Jennings, W. G. (1972). An ergot alkaloid preparation (Hydergine) versus placebo for treatment of symptoms of cerebrovascular insufficiency: double-blind study. J. Am. Geriatr. Soc., 20, 407–12.CrossRefGoogle Scholar
  6. Judge, T. G. and Urquhart, A. (1972). Naftidrofuryl — a double-blind cross-over study in the elderly. Current Med. Res. Opinion, 1, 166–72.CrossRefGoogle Scholar
  7. Katzman, R. (1981). Early detection of senile dementia. Hosp. Prac, 16, No. 15, 61.Google Scholar
  8. Lazzari, R., Franzese, A., Cheirichetti, S. M., Vibelli, C., Rudelli, G., Passeri, M. and Cucinotta, D. (1983). Multicentre double-blind placebo-controlled long-term clinical trial of Hydergine in chronic senile cerebral insufficiency: an interim report. In Agnoli, A., Crepaldi, G., Spano, P. E. and Trabucci, M. (eds), Aging Brain and Ergot Alkaloids, Raven Press, New York, 347–71.Google Scholar
  9. Lezak, M. D. (1985). Neuropsychological assessment. In Vinken, P. J., Bruyn, G. W. and Klawans, H. L. (eds), Handbook of Clinical Neurology, Volume 1 No. 45, Elsevier, Amsterdam and New York, 515–30.Google Scholar
  10. McConnachie, R. (1973). A clinical trial comparing ‘Hydergine’ with placebo in the treatment of cerebrovascular insufficiency in elderly patients. Current Med. Res. Opinion, 1, 463–8.CrossRefGoogle Scholar
  11. Nelson, J. J. (1975). Relieving select symptoms of the elderly. Geriatrics, 30, 133–42.Google Scholar
  12. Qureschi, K. N. and Hodkinson, H. M. (1974). Evaluation of a ten-question mental test in the institutionalised elderly. Age Aging, 3, 152–6.CrossRefGoogle Scholar
  13. Rao, D. B. and Norris, J. R. (1972). A double-blind investigation of Hydergine in the treatment of cerebrovascular insufficiency in the elderly. Johns Hopkins Med. J., 130, 317–24.Google Scholar
  14. Rehman, S. A. (1973). Two trials comparing ‘Hydergine’ with placebo in the treatment of patients suffering from cerebrovascular insufficiency. Current Med. Res. Opinion, 1, 456–62.CrossRefGoogle Scholar
  15. Rivera, V. M., Meyer, J. S., Baer, P. E., Faibish, G. M., Mathew, N. T. and Hartmann, A. (1974). Vertebrobasilar arterial insufficiency with dementia. Controlled trial of treatment with betahistine. J. Amer. Geriatr. Soc., 22, 397–406.CrossRefGoogle Scholar
  16. Robinson, K. (1972). A double-blind clinical trial of naftidrofuryl in cerebrovascular disorders. Med. Dig. Dec, 50–55.Google Scholar
  17. Rosen, H. J. (1975). Mental decline in the elderly: pharmacotherapy (ergot alkaloids verus papaverine). J. Amer. Geriatr. Soc., 23, 169–74.CrossRefGoogle Scholar
  18. Scrip (Leading Article) (1985). 1037, 8.Google Scholar
  19. Tamminga, C. A., Durso, R., Fedro, P. and Chase, T. N. (1982). Vasopressin studies in Alzheimer’s disease. Psycho. Pharmacol. Bull., 18, 48–9.Google Scholar
  20. Thibault, A. (1974). A double-blind evaluation of ‘Hydergine’ and placebo in the treatment of patients with organic brain syndrome and cerebral arteriosclerosis in a nursing home. Current Med. Res. Opinion, 2, 482–7.CrossRefGoogle Scholar
  21. Wallace, M. G., Capildeo, R. and Rose, F. C. (1983). Multicentre general practitioner trial of Hydergine in dementia using a screening programme. In Agnoli, A., Crepaldi, G., Spano, P. E. and Trabucci, M. (eds), Aging Brain and Ergot Alkaloids, Raven Press, New York, 339–46.Google Scholar
  22. Wettstein, A. (1983). No effect from double-blind trial of physostigmine and lecithin in Alzheimer’s disease. Ann. Neurol., 12, 210–12.CrossRefGoogle Scholar
  23. Yesavage, J. A., Tinklenburg, J. R., Hollister, L. E. and Berger, P. A. (1979). Vasodilators in senile dementias — a review of the literature. Arch. Gen. Psychiatr., 36, 220–23.CrossRefGoogle Scholar
  24. Young, J., Hall, P. and Blakemore, L. (1974). Treatment of the cerebral manifestations of arteriosclerosis with cyclandelate. Brit. J. Psychiat., 124, 177–80.CrossRefGoogle Scholar

Copyright information

© The contributors 1988

Authors and Affiliations

  • J. M. S. Pearce
  • M. G. Wallace
  • R. Capildeo

There are no affiliations available

Personalised recommendations